This relatively contemporary study with a median follow up of 6.2 years in over 12,000 patients revealed a neutral effect on cardiovascular outcomes and cancers but confirmed increased rates of hypoglycemia and weight gain in insulin treated patients both of which may adversely affect cardiovascular outcomes over a more longer time period. The gene discussed is INS; the disease is cancer.